Skip to main content

Table 1 Model outcomes for several compliance losses with generic substitution

From: A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

  Branded Risp. Generic Risp. 0% Generic Risp. 2.5% Generic Risp. 5% Generic Risp. 7.5% Generic Risp. 10%
# Relapses 3.98 3.98 3.99 4.01 4.02 4.04
Total relapse time (yrs) 2.05 2.05 2.06 2.07 2.07 2.08
Average PANSS score 62.9 62.9 63.0 63.2 63.4 63.5
Time on risperidone (yrs) 1.16 1.16 1.14 1.13 1.12 1.10
% on risperidone after 1 yr 60.7% 60.7% 59.3% 57.9% 56.5% 55.1%
Total QALYs (disc) 3.622 3.622 3.618 3.615 3.611 3.607
Costs (discounted by component)       
Home (pp) €0 €0 €0 €0 €0 €0
Home (ia) €254 €254 €255 €256 €257 €258
Sheltered Living €7,120 €7,124 €7,136 €7,145 €7,159 €7,182
Day Care €35,188 €35,229 €35,329 €35,479 €35,654 €35,758
Hospital €37,124 €37,088 €37,440 €37,700 €37,971 €38,267
Long-term care institution €958 €953 €966 €965 €972 €973
Psych Visits €952 €952 €954 €955 €957 €959
Drug Costs €8,012 €6,778 €6,772 €6,765 €6,760 €6,755
Total Discounted Costs €89,607 €88,378 €88,850 €89,265 €89,730 €90,152
ΔE   0 0.004 0.007 0.011 0.015
ΔC   €1,230 €757 €343 -€123 -€544
ICUR   - €196,243 €46,032 dominant dominant
  1. PANSS = positive and negative syndrome scale, QALYs = quality adjusted life years, ΔE = incremental effects of branded risperidone vs. generic risperidone, ΔC = incremental costs of branded risperidone vs. generic risperidone, ICUR = incremental cost utility ratio of branded risperidone vs. generic risperidone.